Stockscreener 앱 받기
469.49
0.38%
1.79
시간 외 거래:
469.49
전일 마감가:
$467.70
열려 있는:
$465.71
하루 거래량:
373.17K
Relative Volume:
0.84
시가총액:
$20.21B
수익:
$3.13B
순이익/손실:
$1.27B
주가수익비율:
17.79
EPS:
26.3851
순현금흐름:
$1.12B
1주 성능:
+0.12%
1개월 성능:
-5.38%
6개월 성능:
+66.52%
1년 성능:
+33.26%
1일 변동 폭
$462.02
$470.87
1주일 범위
$462.02
$479.41
52주 변동 폭
$266.98
$519.99
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
469.49 | 20.14B | 3.13B | 1.27B | 1.12B | 26.39 |
|
ZTS
Zoetis Inc
|
124.82 | 53.64B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.23 | 54.24B | 29.62B | 260.04M | 5.51B | 0.0787 |
|
HLN
Haleon Plc Adr
|
10.47 | 45.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.08 | 37.94B | 17.39B | 1.43B | 774.28M | 1.219 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Finviz
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) - Finviz
Mutual of America Capital Management LLC Acquires 4,036 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 13,401 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR - MarketBeat
What's Going On With United Therapeutics Stock Monday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics reports positive phase 1 results for bioengineered liver By Investing.com - Investing.com Canada
How Investors May Respond To United Therapeutics (UTHR) Positive Early Data For Bioengineered Liver Support Device - Yahoo Finance
United Therapeutics reports positive phase 1 results for bioengineered liver - Investing.com
Retirement Systems of Alabama Sells 18,709 Shares of United Therapeutics Corporation $UTHR - MarketBeat
World’s first FDA-cleared bioengineered liver trial meets survival goal - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: Potential Upside and Robust Growth in the Biotech Sphere - DirectorsTalk Interviews
United Therapeutics appoints biomedical research leader to board By Investing.com - Investing.com Nigeria
United Therapeutics Appoints Kevin J. Tracey To Board - citybiz
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026 - marketscreener.com
United Therapeutics appoints biomedical research leader to board - Investing.com
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors - United Therapeutics Investor Relations
Element Squared LLC Buys 5,027 Shares of United Therapeutics Corp (UTHR) - GuruFocus
Marquette Asset Management, LLC Buys 1 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corporation (UTHR): A Bull Case Theory - Finviz
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
United Therapeutics COO sells $10.7 million in UTHR stock - Investing.com
United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension - TipRanks
United Therapeutics Corporation $UTHR Shares Sold by State of Alaska Department of Revenue - MarketBeat
SG Americas Securities LLC Purchases 7,483 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Position Decreased by Nepsis Inc. - MarketBeat
How United Therapeutics Corporation (UTH) stock expands through international marketsTreasury Yields & Verified Swing Trading Watchlists - Улправда
Is United Therapeutics Corporation stock a good choice for value investorsJuly 2025 Recap & AI Enhanced Execution Alerts - Улправда
MannKind Provides Business Updates and 2026 Growth Drivers - Benzinga
Robeco Institutional Asset Management B.V. Has $38.19 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) COO Sells $7,127,932.50 in Stock - MarketBeat
Director Jan Malcolm Sells Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (UTHR): UBS Raises Price Target, Maintains B - GuruFocus
Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Performance Tethered To Its Attractive Financial Prospects? - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares - MarketBeat
United Therapeutics Corporation (UTHR) Stock Analysis: A Healthcare Giant with Strong Growth Potential and Robust Analyst Support - DirectorsTalk Interviews
Biotech developing organ transplant tech steps onto J.P. Morgan stage - Stock Titan
United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 4,944 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics Corporation $UTHR Position Increased by Cwm LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares - MarketBeat
United Therapeutics EVP & General Counsel Sells 11,000 Shares - TradingView — Track All Markets
United Therapeutics president sells $3.5m in stock - MSN
United Therapeutics Insider Sold Shares Worth $5,644,954, According to a Recent SEC Filing - marketscreener.com
Death Cross: Can United Therapeutics Corporation stock sustain market leadershipTrend Reversal & AI Based Buy/Sell Signal Reports - moha.gov.vn
Pacer Advisors Inc. Decreases Position in United Therapeutics Corporation $UTHR - MarketBeat
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
1.38%
자본화:
|
볼륨(24시간):